Sales & Marketing News | pharmaphorum

News

Unicycive eyes June FDA verdict for hyperphosphataemia drug

The FDA has started a review of Unicycive Therapeutics' drug for hyperphosphataemia in patients with chronic kidney disease (CKD) who need dialysis, which hopes to improve on 'onerous' phos

News

window into laboratory with scientist hard at work

Autolus bags FDA approval for leukaemia cell therapy

Autolus has picked up its first product approval, getting an FDA green light for Aucatzyl as a treatment for patients with aggressive blood cancer acute lymphoblastic leukaemia (ALL).

News

Eisai dials back forecasts for Alzheimer's drug Leqembi

Eisai has retreated from the optimistic view of sales growth for Alzheimer's disease drug Leqembi it held earlier this year as uptake remains sluggish.

News

AZ confirms China president has been detained

AstraZeneca has revealed that its top executive in China, Leon Wang, has been detained by Chinese authorities, after confirming he was under investigation last week.

News

Sarepta pulls plug on Duchenne exon-skipping drug

Sarepta Therapeutics has decided not to continue the development of vesleteplirsen, a follow-up to its Duchenne muscular dystrophy (DMD) therapy Exondys 51.

News

Nick Green, president and CEO of Avid Bioservices

Avid Bioservices to go private in $1.1bn private equity deal

Anglo-US contract development and manufacturing organisation (CDMO) Avid Bioservices has agreed a deal to be acquired by private equity firms GHO Capital Partners and Ampersand Capital Part

Unicycive eyes June FDA verdict for hyperphosphataemia drug

Autolus bags FDA approval for leukaemia cell therapy

Eisai dials back forecasts for Alzheimer's drug Leqembi

AZ confirms China president has been detained

Sarepta pulls plug on Duchenne exon-skipping drug

Avid Bioservices to go private in $1.1bn private equity deal

The long-delayed promise of the microbiome, with Sam Possemi...

How to meet your physicians where they are online

News

Editor's Picks